Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Validation of the COPD Assessment Test (CAT) as an Outcome Measure in Bronchiectasis.

Finch S, Laska IF, Abo-Leyah H, Fardon TC, Chalmers JD.

Chest. 2019 Nov 12. pii: S0012-3692(19)34198-4. doi: 10.1016/j.chest.2019.10.030. [Epub ahead of print]

PMID:
31730832
2.

Pregnancy Zone Protein Is Associated with Airway Infection, Neutrophil Extracellular Trap Formation, and Disease Severity in Bronchiectasis.

Finch S, Shoemark A, Dicker AJ, Keir HR, Smith A, Ong S, Tan B, Choi JY, Fardon TC, Cassidy D, Huang JTJ, Chalmers JD.

Am J Respir Crit Care Med. 2019 Oct 15;200(8):992-1001. doi: 10.1164/rccm.201812-2351OC.

3.

Pulmonary rehabilitation after exacerbation of bronchiectasis: a pilot randomized controlled trial.

Chalmers JD, Crichton ML, Brady G, Finch S, Lonergan M, Fardon TC.

BMC Pulm Med. 2019 May 6;19(1):85. doi: 10.1186/s12890-019-0856-0.

4.

The impact of acute air pollution fluctuations on bronchiectasis pulmonary exacerbation: a case-crossover analysis.

Goeminne PC, Cox B, Finch S, Loebinger MR, Bedi P, Hill AT, Fardon TC, de Hoogh K, Nawrot TS, Chalmers JD.

Eur Respir J. 2018 Jul 27;52(1). pii: 1702557. doi: 10.1183/13993003.02557-2017. Print 2018 Jul.

PMID:
29903857
5.

The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis.

Araújo D, Shteinberg M, Aliberti S, Goeminne PC, Hill AT, Fardon TC, Obradovic D, Stone G, Trautmann M, Davis A, Dimakou K, Polverino E, De Soyza A, McDonnell MJ, Chalmers JD.

Eur Respir J. 2018 Jan 31;51(2). pii: 1701953. doi: 10.1183/13993003.01953-2017. Print 2018 Feb.

6.

Characterization of the "Frequent Exacerbator Phenotype" in Bronchiectasis.

Chalmers JD, Aliberti S, Filonenko A, Shteinberg M, Goeminne PC, Hill AT, Fardon TC, Obradovic D, Gerlinger C, Sotgiu G, Operschall E, Rutherford RM, Dimakou K, Polverino E, De Soyza A, McDonnell MJ.

Am J Respir Crit Care Med. 2018 Jun 1;197(11):1410-1420. doi: 10.1164/rccm.201711-2202OC.

PMID:
29357265
7.

Anti-Pseudomonas aeruginosa IgG antibodies and chronic airway infection in bronchiectasis.

Suarez-Cuartin G, Smith A, Abo-Leyah H, Rodrigo-Troyano A, Perea L, Vidal S, Plaza V, Fardon TC, Sibila O, Chalmers JD.

Respir Med. 2017 Jul;128:1-6. doi: 10.1016/j.rmed.2017.05.001. Epub 2017 May 2.

8.

The heterogeneity of systemic inflammation in bronchiectasis.

Saleh AD, Chalmers JD, De Soyza A, Fardon TC, Koustas SO, Scott J, Simpson AJ, Brown JS, Hurst JR.

Respir Med. 2017 Jun;127:33-39. doi: 10.1016/j.rmed.2017.04.009. Epub 2017 Apr 17.

9.

Bronchiectasis Rheumatoid Overlap Syndrome Is an Independent Risk Factor for Mortality in Patients With Bronchiectasis: A Multicenter Cohort Study.

De Soyza A, McDonnell MJ, Goeminne PC, Aliberti S, Lonni S, Davison J, Dupont LJ, Fardon TC, Rutherford RM, Hill AT, Chalmers JD.

Chest. 2017 Jun;151(6):1247-1254. doi: 10.1016/j.chest.2016.12.024. Epub 2017 Jan 16.

10.

Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis.

Chalmers JD, Moffitt KL, Suarez-Cuartin G, Sibila O, Finch S, Furrie E, Dicker A, Wrobel K, Elborn JS, Walker B, Martin SL, Marshall SE, Huang JT, Fardon TC.

Am J Respir Crit Care Med. 2017 May 15;195(10):1384-1393. doi: 10.1164/rccm.201605-1027OC.

11.

Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study.

McDonnell MJ, Aliberti S, Goeminne PC, Restrepo MI, Finch S, Pesci A, Dupont LJ, Fardon TC, Wilson R, Loebinger MR, Skrbic D, Obradovic D, De Soyza A, Ward C, Laffey JG, Rutherford RM, Chalmers JD.

Lancet Respir Med. 2016 Dec;4(12):969-979. doi: 10.1016/S2213-2600(16)30320-4. Epub 2016 Nov 16.

12.

Characterization of bronchiectasis in the elderly.

Bellelli G, Chalmers JD, Sotgiu G, Dore S, McDonnell MJ, Goeminne PC, Dimakou K, Skrbic D, Lombi A, Pane F, Obradovic D, Fardon TC, Rutherford RM, Pesci A, Aliberti S.

Respir Med. 2016 Oct;119:13-19. doi: 10.1016/j.rmed.2016.08.008. Epub 2016 Aug 17.

13.

Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts.

McDonnell MJ, Aliberti S, Goeminne PC, Dimakou K, Zucchetti SC, Davidson J, Ward C, Laffey JG, Finch S, Pesci A, Dupont LJ, Fardon TC, Skrbic D, Obradovic D, Cowman S, Loebinger MR, Rutherford RM, De Soyza A, Chalmers JD.

Thorax. 2016 Dec;71(12):1110-1118. doi: 10.1136/thoraxjnl-2016-208481. Epub 2016 Aug 11.

14.

The generalizability of bronchiectasis randomized controlled trials: A multicentre cohort study.

Chalmers JD, McDonnell MJ, Rutherford R, Davidson J, Finch S, Crichton M, Dupont L, Hill AT, Fardon TC, De Soyza A, Aliberti S, Goeminne P.

Respir Med. 2016 Mar;112:51-8. doi: 10.1016/j.rmed.2016.01.016. Epub 2016 Jan 29.

15.

Clinical phenotypes in adult patients with bronchiectasis.

Aliberti S, Lonni S, Dore S, McDonnell MJ, Goeminne PC, Dimakou K, Fardon TC, Rutherford R, Pesci A, Restrepo MI, Sotgiu G, Chalmers JD.

Eur Respir J. 2016 Apr;47(4):1113-22. doi: 10.1183/13993003.01899-2015. Epub 2016 Feb 4.

16.

Secreted mucins and airway bacterial colonization in non-CF bronchiectasis.

Sibila O, Suarez-Cuartin G, Rodrigo-Troyano A, Fardon TC, Finch S, Mateus EF, Garcia-Bellmunt L, Castillo D, Vidal S, Sanchez-Reus F, Restrepo MI, Chalmers JD.

Respirology. 2015 Oct;20(7):1082-8. doi: 10.1111/resp.12595. Epub 2015 Jul 14.

17.

Invasive pulmonary aspergillosis post extracorporeal membrane oxygenation support and literature review.

Parcell BJ, B C Raju PK, Johnson EM, Fardon TC, Olver WJ.

Med Mycol Case Rep. 2014 Feb 10;4:12-5. doi: 10.1016/j.mmcr.2014.01.003. eCollection 2014 Apr.

18.

The bronchiectasis severity index. An international derivation and validation study.

Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, Poppelwell L, Salih W, Pesci A, Dupont LJ, Fardon TC, De Soyza A, Hill AT.

Am J Respir Crit Care Med. 2014 Mar 1;189(5):576-85. doi: 10.1164/rccm.201309-1575OC.

19.

A multidisciplinary intervention to reduce antibiotic duration in lower respiratory tract infections.

Murray C, Shaw A, Lloyd M, Smith RP, Fardon TC, Schembri S, Chalmers JD.

J Antimicrob Chemother. 2014 Feb;69(2):515-8. doi: 10.1093/jac/dkt362. Epub 2013 Sep 10.

PMID:
24022067
20.

A randomized primary care trial of steroid titration against mannitol in persistent asthma: STAMINA trial.

Lipworth BJ, Short PM, Williamson PA, Clearie KL, Fardon TC, Jackson CM.

Chest. 2012 Mar;141(3):607-615. doi: 10.1378/chest.11-1748. Epub 2011 Oct 13.

PMID:
21998259
21.

Supervised step-down of inhaled corticosteroids in the community--an observational study.

Clearie KL, Jackson CM, Fardon TC, Williamson PA, Vaidyanathan S, Burns P, Lipworth BJ.

Respir Med. 2011 Apr;105(4):558-65. doi: 10.1016/j.rmed.2010.10.004. Epub 2010 Dec 8.

22.

Proof of concept study to evaluate step-down therapy with inhaled corticosteroid alone or additive therapy on surrogate inflammatory markers in asthma.

McKinlay L, Williamson PA, Short PM, Fardon TC, Lipworth BJ.

Br J Clin Pharmacol. 2011 Jan;71(1):128-31. doi: 10.1111/j.1365-2125.2010.03795.x.

23.

Paradoxical trough effects of triple therapy with budesonide/formoterol and tiotropium bromide on pulmonary function outcomes in COPD.

Williamson PA, Short PM, Clearie KL, Vaidyanathan S, Fardon TC, Howaniec LJ, Lipworth BJ.

Chest. 2010 Sep;138(3):595-604. doi: 10.1378/chest.10-0247. Epub 2010 Apr 23.

PMID:
20418370
24.

Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic.

Chalmers JD, Al-Khairalla M, Short PM, Fardon TC, Winter JH.

J Antimicrob Chemother. 2010 Apr;65(4):608-18. doi: 10.1093/jac/dkq038. Epub 2010 Feb 23. Review.

25.

The role of measuring airway hyperresponsiveness and inflammatory biomarkers in asthma.

Currie GP, Fardon TC, Lee DK.

Ther Clin Risk Manag. 2005 Jun;1(2):83-92.

26.

Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate.

Tayab ZR, Fardon TC, Lee DK, Haggart K, McFarlane LC, Lipworth BJ, Hochhaus G.

Br J Clin Pharmacol. 2007 Nov;64(5):698-705. Epub 2007 May 17.

27.

Combined mediator blockade or topical steroid for treating the unified allergic airway.

Barnes ML, Menzies D, Fardon TC, Burns P, Wilson AM, Lipworth BJ.

Allergy. 2007 Jan;62(1):73-80.

PMID:
17156345
28.

Respiratory symptoms, pulmonary function, and markers of inflammation among bar workers before and after a legislative ban on smoking in public places.

Menzies D, Nair A, Williamson PA, Schembri S, Al-Khairalla MZ, Barnes M, Fardon TC, McFarlane L, Magee GJ, Lipworth BJ.

JAMA. 2006 Oct 11;296(14):1742-8.

PMID:
17032987
29.

Effects of intranasal corticosteroid on nasal adenosine monophosphate challenge in persistent allergic rhinitis.

Barnes ML, Biallosterski BT, Fujihara S, Gray RD, Fardon TC, Lipworth BJ.

Allergy. 2006 Nov;61(11):1319-25.

PMID:
17002709
30.

Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis.

Barnes ML, Ward JH, Fardon TC, Lipworth BJ.

Clin Exp Allergy. 2006 May;36(5):676-84.

PMID:
16650054
31.

A comparison of 2 extrafine hydrofluoroalkane-134a-beclomethasone formulations on methacholine hyperresponsiveness.

Fardon TC, Burns P, Barnes ML, Lipworth BJ.

Ann Allergy Asthma Immunol. 2006 Mar;96(3):422-30.

PMID:
16597076
32.

Decongestant effects of nasal xylometazoline and mometasone furoate in persistent allergic rhinitis.

Barnes ML, Biallosterski BT, Gray RD, Fardon TC, Lipworth BJ.

Rhinology. 2005 Dec;43(4):291-5.

PMID:
16405274
33.

Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma.

Fardon TC, Lee DK, Hodge MR, Lipworth BJ.

Ann Allergy Asthma Immunol. 2005 Sep;95(3):259-65.

PMID:
16200817
34.

Evaluation of an abbreviated adenosine monophosphate bronchial challenge.

Fardon TC, Hodge MR, Lipworth BJ.

Chest. 2005 Jun;127(6):2222-5.

PMID:
15947340
35.

An own GOAL or a real breakthrough?

Fardon TC, Lipworth BJ.

Am J Respir Crit Care Med. 2005 May 1;171(9):1060; author reply 1061. No abstract available.

PMID:
15849331
36.

Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma.

Lee DK, Fardon TC, Bates CE, Haggart K, McFarlane LC, Lipworth BJ.

Chest. 2005 Mar;127(3):851-60.

PMID:
15764767
37.

Comparative cutoff points for adenosine monophosphate and methacholine challenge testing.

Fardon TC, Fardon EJ, Hodge MR, Lipworth BJ.

Ann Allergy Asthma Immunol. 2004 Oct;93(4):365-72.

PMID:
15521373
38.

Lower thresholds for bronchial challenge testing.

Fardon TC, Currie G, Lee DK, Lipworth BJ.

Allergy. 2004 Oct;59(10):1125-6. No abstract available. Erratum in: Allergy. 2005 Jul;60(7):975. Fardon, Tom [corrected to Fardon, Tom C]; Lee, Daniel [corrected to Lee, Daniel KC]; Lipworth, Brian [corrected to Lipworth, Brian J].

PMID:
15355475
39.

Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate.

Fardon TC, Lee DK, Haggart K, McFarlane LC, Lipworth BJ.

Am J Respir Crit Care Med. 2004 Nov 1;170(9):960-6. Epub 2004 Jun 7.

PMID:
15184207
40.
41.

Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers.

Lipworth BJ, Fardon TC.

J Allergy Clin Immunol. 2004 Jan;113(1):178; author reply 178-9. No abstract available.

PMID:
14713929

Supplemental Content

Loading ...
Support Center